Making it Better - A Strategy for Pharmacy in the Community

Strategy for Pharmacy in the community

Making It Better - A Strategy for Pharmacy in the Community (PDF 233 KB)

A Strategy for Community Pharmacy (Consultation Paper)

Comprehensive Review of the Pharmacy Workforce (PDF 474 KB)

Final Report May 2001

Pharmacy Review Group Report

Pharmacy Review Group Report (PDF, 420KB) Indecon Assessment of the 1996 Pharmacy Regulations (PDF, 430KB) Indecon Review of Proposed Regulatory Models for the Pharmacy Sector (PDF, 400KB)  

Community Pharmacy Contractor Agreement for Provision of Community Pharmacy Services Under the Health Act 1970

MEMORANDUM OF AGREEMENT BETWEEN THE DEPARTMENT OF HEALTH AND THE IRISH PHARMACEUTICAL UNION IN RESPECT OF THE PROVISION OF COMMUNITY PHARMACY SERVICES UNDER THE HEALTH ACT, 1970 Read the memorandum  

Report of the Independent Body on Pharmacy Contract Pricing

Report of the Independent Body on Pharmacy Contract Pricing On 18 February 2008 the Minister for Health and Children announced the appointment of an Independent Body to recommend a new, interim community pharmacy dispensing fee for the General Medical Service (GMS), Drugs Payment Scheme (DPS) and other community drug schemes.The Terms of Reference for the Independent Body on Pharmacy Contract Pricing are as follows: â?oTo advise the Minister for Health and Children on the appropriate level of dispensing fee to be paid to community pharmacists for existing services provided under the GMS and community drug schemes having regard to: Click here to download PDF: 110kb

Orchard Pharmacy

Engaging the community through a health column in the local press under the direction of the Southern HSSB. Outcome: This ongoing project is working towards promoting health care in the wider community and enabling the general public to better understand the range of services offered by community pharmacy. The health column is publicised in the local press across the SHSSB area and has worked to increase people's awareness of health and has focused on local needs and information, linking in with national and local health promoting campaigns

Windsor Pharmacy - Valerie Addy

To date this project has underwent phase 1 and is undergoing the implementation of phase 2. The first phase aimed to make students aware of issues surrounding STIs and their health implications. In phase two, the project aims at determining the most appropriate means of disseminating information about sexually transmitted diseases.

Colin Community Area Pharmacy Partnership

This project has worked towards promoting positive mental health by integrating pharmacy services with other local support structures already in existence to support those experiencing mental health issues.

Belcoo Pharmacy

To promote the health and well-being amongst families in the rural and isolated community of Belcoo by focusing on the children, their health and the positive message they can bring to their families.

Frank McCaughan's Pharmacy - James McCaughan

McCaughan's pharmacy in this project will work with Rural Support to address the needs of farmers, identify causes of stress, improve their ability to manage stress and increase their access to services available to them. Infomation events will be held at the local mart and the pharmacist will be on hand to offer 1-1 support and signposting. An aspect of this project is to train up mart staff so to make it sustainable on a longer term basis.

Parkes Pharmacy

This is a level 3 project, the group have previously been funded twice at level 2. Gilford is a rurally isolated area with little community involvement. Previous projects have tried to connect the pharmacist into the local community and have had some success in doing so. The approach they will use in this project is a mix between 1-1 support but they will also recognise the importance of skilling up people and working with groups. It is hoped that after this project the pharmacy will become a meeting point for the community.

Using the costs of drug therapy to screen patients for a community pharmacy-based medication review program

Objectives: To measure the positive predictive value (PPV) of the cost of drug therapy (threshold = 2000 Swiss francs [CHF], US$1440, <euro>1360) as a screening criterion for identifying patients who may benefit from medication review (MR). To describe identified drug-related problems (DRPs) and expense problems (EPs), and to estimate potential savings if all recommendations were accepted. Setting Five voluntary Swiss community pharmacies. Methods: Of 12,680 patients, 592 (4.7%) had drug therapy costs exceeding 2000 CHF over a six-month period from July 1 to December 31, 2002. This threshold limit was set to identify high-risk patients for DRPs and EPs. Three pharmacists consecutively conducted a medication review based on the pharmaceutical charts of 125 sampled patients who met the inclusion criterion. Main outcome measure: The PPV of a threshold of 2000 CHF for identifying patients who might benefit from a MR: true positives were patients with at least one DRP, while false positives were patients with no DRP. Results: The selection based on this criterion had a PPV of 86% for detecting patients with at least one DRP and 95% if EPs were also considered. There was a mean of 2.64 (SD = 2.20) DRPs per patient and a mean of 2.14 (SD = 1.39) EPs per patient. Of these patients, 90% were over 65 years old or were treated with at least five chronic medications, two common criteria for identifying patients at risk of DRPs. The main types of DRPs were drug-drug interactions, compliance problems and duplicate drugs. Mean daily drug cost per patient was CHF 14.87 (US$10.70, <euro>10.10). A potential savings of CHF 1.67 (US$1.20, <euro>1.14) per day (11%) was estimated if all recommendations to solve DRPs and EPs suggested herein were implemented. Conclusion: Further studies should investigate whether the potential benefit of medication reviews in preventing DRPs and containing costs in this patient group can be confirmed in a real practice environment. [Authors]

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice.

BACKGROUND In Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use. METHODS This was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured to describe the committee's activity were number of drugs assessed per year and number of drugs included in any of these settings: without restrictions, with criteria for use, and not included in formulary. These drugs were also analyzed by therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib were issued in accordance with PTC drug use criteria. RESULTS The PTC received requests for inclusion of 40 drugs, of which 32 were included in the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs included. In total, 293 patients were treated with the four cancer drugs in eight different therapeutic indications. The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma. CONCLUSION The degree of compliance with criteria for use of cancer drugs was reasonably high. PTC functions need to be changed so that they can carry out more innovative tasks, such as monitoring conditions for drug use.